Effects of Hydroxyurea Therapy on Inflammatory Markers and Indices in Patients with BCR-ABL Negative Myeloproliferative Neoplasms
Istanbul Medical Journal · 30.10.2026
DOI: 10.4274/imj.galenos.2026.86382 ↗Kurz gefasst
Fachartikel in der Zeitschrift Istanbul Medical Journal, online erschienen am 30.10.2026. Verfasst von Oğuz Altunok und 2 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Introduction
Chronic inflammation plays a central role in the pathogenesis and progression of Breakpoint Cluster Region- Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL)–negative myeloproliferative neoplasms (MPNs). Although hydroxyurea is widely used as a cytoreductive agent in this patient population, its impact on systemic inflammation remains unclear. This study aimed to evaluate the effect of hydroxyurea on inflammatory markers and indices in patients with MPNs.
Methods
In this retrospective study, 298 patients diagnosed with BCR-ABL–negative MPNs who were followed between 2010 and 2022 were analyzed. Patients were classified as polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), or MPN-unclassifiable (MPN-u) according to the 2016 World Health Organization criteria. Laboratory parameters including leukocyte, neutrophil, lymphocyte, and platelet counts, C-reactive protein (CRP), and lactate dehydrogenase (LDH) were recorded at baseline and at months 3, 6, and 12. Inflammatory indices, including the neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SIII), were calculated. Statistical analyses were performed using non-parametric tests.
Results
Of the 298 patients, 59.4% were male, with a median age of 57 years. The cohort included PV (32.5%), ET (35.2%), PMF (8.7%), and MPN-u (23.5%). Hydroxyurea was used in 158 patients, while 126 patients were followed without cytoreductive therapy. Significant reductions in leukocyte and neutrophil counts were observed in the hydroxyurea group at months 0-3, 0-6, and 0-12 (p
Zitieren
APA
Altunok, O., Serin, İ., & Yokuş, O. (2026). Effects of Hydroxyurea Therapy on Inflammatory Markers and Indices in Patients with BCR-ABL Negative Myeloproliferative Neoplasms. Istanbul Medical Journal. https://doi.org/10.4274/imj.galenos.2026.86382
Vancouver
Altunok O, Serin İ, Yokuş O. Effects of Hydroxyurea Therapy on Inflammatory Markers and Indices in Patients with BCR-ABL Negative Myeloproliferative Neoplasms. Istanbul Medical Journal. 2026. doi:10.4274/imj.galenos.2026.86382
BibTeX
@article{Altunok2026,
author = {Altunok, Oğuz and Serin, İstemi and Yokuş, Osman},
title = {Effects of Hydroxyurea Therapy on Inflammatory Markers and Indices in Patients with BCR-ABL Negative Myeloproliferative Neoplasms},
journal = {Istanbul Medical Journal},
year = {2026},
doi = {10.4274/imj.galenos.2026.86382}
}
EUVIMED